Mercy Ships Announces the Global Mercy, World’s Largest NGO Hospital Ship – Plans to Sail Late 2021

October 6, 2020

Mercy Ships announced a first look at the construction of the world’s largest NGO hospital ship which plans to sail to Africa in late 2021 under the name of Global Mercy.

Mercy Ships, a faith-based global organization powered by charitable donors and volunteers, has been providing world-class surgical care to those in need for more than 40 years, free of charge.

“The Global Mercy will be a true modern marvel— a fully custom-built hospital ship with customized instruments, state-of-the-art technology and highly-trained talent of a modern hospital,” said Rosa Whitaker, president of Mercy Ships. “It also represents a unique call-to-action for anyone called to serve, and it presents the opportunity for people to use their skill set to positively impact global healthcare.”

According to the Lancet Global Surgery 2030 Report, an estimated number of 16.9 million people die yearly due to lack of access to surgical care. Over 93 percent of the population of sub-Saharan Africa do not have access to safe and timely surgery.1 As COVID-19 threatens the stability of already fragile healthcare systems globally, the need to provide basic life-saving care is greater than ever, especially in low-to-middle income countries. The Global Mercy will deliver a safe and clean environment to various African nations, providing help and resources from some of the most well-trained physicians in the world. Over the vessel’s 50 year expected lifespan, it is estimated that more than 150,000 lives will be changed onboard through surgery alone.

In addition to providing surgeries, the Global Mercy will be outfitted with state-of-the-art training spaces including a simulation lab with virtual and augmented reality, mannequins and other training tools and simulated post-op care space, which allow trainers to simulate local conditions and limitations in order to teach best practices in low-resource environments.

The 174-meter, 37,000-ton ship will have six operating rooms and house over 600 volunteers from around the globe representing many disciplines including surgeons, maritime crew, cooks, teachers, electricians, the host staff and more. The ship will also feature a 682-seat auditorium, student academy, gymnasium, pool, café, shop and library – all of which have been designed to accommodate up to 950 crew onboard when docked in port.

The Global Mercy will join the current flagship Africa Mercy, more than doubling the impact of volunteers and services provided by the charity. For more information about Mercy Ships, updates on Global Mercy or how to volunteer or donate, please visit here.

Mercy Ships uses hospital ships to deliver free, world-class healthcare services, capacity building, and sustainable development to those with little access in the developing world. Founded in 1978 by Don and Deyon Stephens, Mercy Ships has worked in more than 55 developing countries, providing services valued at more than $1.7 billion and directly benefitting more than 2.8 million people. Our ships are crewed by volunteers from over 50 nations, with an average of over 2000 volunteers each year. Professionals including surgeons, dentists, nurses, healthcare trainers, teachers, cooks, seamen, engineers, and agriculturalists donate their time and skills. With 16 national offices and an Africa Bureau, Mercy Ships seeks to transform individuals and serve nations.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  
Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.

By using this website you agree to accept Medical Device News Magazine Privacy Policy